These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16828888)

  • 1. Recent development of therapeutics for chronic HCV infection.
    Huang Z; Murray MG; Secrist JA
    Antiviral Res; 2006 Sep; 71(2-3):351-62. PubMed ID: 16828888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
    Chen SH; Tan SL
    Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
    Koch U; Narjes F
    Curr Top Med Chem; 2007; 7(13):1302-29. PubMed ID: 17627559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance mutations against HCV protease inhibitors and antiviral drug design.
    Shang L; Lin K; Yin Z
    Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
    Tsantrizos YS
    Curr Opin Investig Drugs; 2009 Aug; 10(8):871-81. PubMed ID: 19649931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New targets for antiviral therapy of chronic hepatitis C.
    Bühler S; Bartenschlager R
    Liver Int; 2012 Feb; 32 Suppl 1():9-16. PubMed ID: 22212566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial watch: Protease inhibitors show promise against HCV.
    Nat Rev Drug Discov; 2009 Jan; 8(1):11. PubMed ID: 19116621
    [No Abstract]   [Full Text] [Related]  

  • 9. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
    Naggie S; Patel K; McHutchison J
    J Antimicrob Chemother; 2010 Oct; 65(10):2063-9. PubMed ID: 20688770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
    Morikawa K; Lange CM; Gouttenoire J; Meylan E; Brass V; Penin F; Moradpour D
    J Viral Hepat; 2011 May; 18(5):305-15. PubMed ID: 21470343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of NS3 protease inhibitors in HCV infection.
    Goudreau N; Llinàs-Brunet M
    Expert Opin Investig Drugs; 2005 Sep; 14(9):1129-44. PubMed ID: 16144497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.
    Beaulieu PL; Tsantrizos YS
    Curr Opin Investig Drugs; 2004 Aug; 5(8):838-50. PubMed ID: 15600240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.
    Kwong AD; McNair L; Jacobson I; George S
    Curr Opin Pharmacol; 2008 Oct; 8(5):522-31. PubMed ID: 18835365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus.
    Kamal S; Shahzad A; Rehman K; Tariq K; Akash MSH; Imran M; Assiri MA
    Curr Med Chem; 2024; 31(15):2052-2072. PubMed ID: 37855348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current drug discovery strategies for treatment of hepatitis C virus infection.
    Cheng KC; Gupta S; Wang H; Uss AS; Njoroge GF; Hughes E
    J Pharm Pharmacol; 2011 Jul; 63(7):883-92. PubMed ID: 21635253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal treatment with telaprevir for chronic HCV infection.
    Jesudian AB; Jacobson IM
    Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New horizons in hepatitis C antiviral therapy with direct-acting antivirals.
    Aghemo A; De Francesco R
    Hepatology; 2013 Jul; 58(1):428-38. PubMed ID: 23467911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.